# Professional Value-based Reimbursement (Professional VBR) Program new reporting metrics

#### October 2026 adjustment will be based on new metrics

For the measurement period beginning in 2025, the Professional Value-Based Reimbursement (Professional VBR) program metric list will be updated to rely on "appropriateness" and "quality" metrics supplied by Motive Medical Intelligence (Motive). These evidence-based clinical metrics will replace all currently used metrics, aside from generic substitution rate.

**Note**: The updated Motive metrics will not impact program results released in July 2025 and levels that apply October 2025 to September 2026. New reporting will be released July 2026, and updated levels applied in October 2026.

**Specialty changes**: Dermatology and psychology specialties will no longer be included in the Professional VBR program. Primary care will be updated to score in the categories of Adult primary care and Pediatrics.

Below are the specific metrics and weights included in each specialty. We will release complete program details for this update in January 2026, reflecting the new metrics and specialty changes. **Note**: The scoring methodology will remain unchanged.

## Ophthalmology measures

#### Appropriateness of care

Measure name	Weight
Bevacizumab Underuse in Anti-VEGF Injections for Wet AMD	3
Optic Nerve Monitoring Underuse in Primary Open-Angle Glaucoma	2
Prophylactic Antibiotic Overuse with Intravitreal Injections	2
Retinal Examination Underuse in Diabetic Retinopathy	1

#### Online resources

Learn more about our Professional VBR program on our provider website, asuris.com: Contracting & Credentialing>
APM Resources>Professional Value-Based
Reimbursement (VBR).





# Obstetrics & gynecology measures

#### Appropriateness of care

Measure name	Weight
Primary Cesarean Section Overuse for Low-Risk Pregnancy	3
Cervical Cancer Screening Overuse in Older Women	1
Cervical Cancer Screening Overuse in Younger Women	1
TDAP Vaccine Underuse in Pregnancy	1
Group B Strep Testing Underuse in Pregnancy	1
Postpartum Diabetes Screening Underuse	1

#### Quality, generic substitution rate

Measure name	Weight
- Generic prescription substitution rate	1

#### Quality

Measure name	Weight
Laparoscopic Hysterectomy Complication Rate	2
Preexisting Hypertension in Pregnancy: Adherence to Guideline-Directed Care, including:	2
- Recommended Fetal Ultrasound	
- Recommended Group B Streptococcus Screening	
- Recommended Tdap Vaccination	
- Recommended Laboratory Evaluation	
Gestational Diabetes: Adherence to Guideline-Directed Care, including:	2
- Recommended Postpartum Diabetes Screening	
- Recommended Group B Streptococcus Screening	
- Recommended Tdap Vaccination	
Gestational Hypertension/Preeclampsia: Adherence to Guideline-Directed Care, including:	1
- Recommended Tdap Vaccination	
- Recommended Group B Streptococcus Screening	
- Recommended Fetal Ultrasound	
- Recommended Laboratory Evaluation	



# Adult primary care measures

### Appropriateness of care

Measure name	Weight
Lipid Monitoring Underuse with Statins	2
NSAID Overuse in Heart Failure, Hypertension, or CKD	2
HbA1c Monitoring Underuse in Diabetes	2
eGFR Monitoring Underuse in Diabetes	1
Urinary Albumin-to-Creatinine Monitoring Underuse in Diabetes	1
Albuminuria Monitoring Underuse in CKD	1
Mammography Screening Underuse in Eligible Women	1
Moderate- or High-Intensity Statin Underuse in Diabetes	1
Diabetes Screening Underuse in Prediabetes	1
Statin Underuse after Stroke	1
Mammography Overuse in Older Women	1

#### Quality, generic substitution rate

Measure name	Weight
- Generic prescription substitution rate	1

## Pediatrics measures

#### Appropriateness of care

Measure name	Weight
Codeine and Hydrocodone Overuse in Respiratory Tract Infections	3
Routine Urinalysis Overuse	1
Asthma Controller Underuse with Asthma Reliever	2
Advanced Imaging Overuse in Headache	1
Streptococcal Testing Underuse in Antibiotic-Treated Pharyngitis	1
Medication Management Visit Underuse after ADHD Drug Initiation	2

#### Quality

Measure name	Weight
Asthma: Adherence to Guideline-Directed Care, including:	2
- Nonrecommended Montelukast Therapy	
<ul> <li>Recommended Annual Influenza Vaccination</li> </ul>	
- Nonrecommended SABA Monotherapy	

#### Quality, generic substitution rate

Measure name	Weight
- Generic prescription substitution rate	1

